Drug guidance
High-strength insulin glargine for treating type 1 and 2 diabetes mellitus
1 April 2022
Condition
Endocrine and metabolic
Published on 01 Apr 2022
Last Updated on 01 Apr 2022
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has not recommended listing insulin glargine 300 units/ml on the Standard Drug List (SDL) for treating type 1 and 2 diabetes mellitus in view of unfavourable cost-effectiveness compared with insulin glargine 100 units/ml at the price proposed by the manufacturer, and low clinical need.